Back to Agenda
Session 12: Special Regulatory Considerations for Development
Session Chair(s)
Michael Hamrell, PhD, RAC
President
MORIAH Consultants, United States
- Special Protocol Assessment
- Special Development Pathways
- Subpart E (expedited drug development)
- Subpart H (accelerated approval)
- Fast Track
- New Pathways under FDASIA
- Breakthrough Therapy
- Qualified Infectious Disease Product
- Orphan Products
Have an account?